Specify Company / Ticker to Get the Summary
Royalty Pharma Plc
RPRXRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. Address: 110 East 59th Street, New York, NY, United States, 10022
Analytics
WallStreet Target Price
40.04 USDP/E ratio
17.07Dividend Yield
2.70 %Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures RPRX
Dividend Analytics RPRX
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
4 years5Y Average Payout Ratio
196.40 %Dividend History RPRX
Stock Valuation RPRX
Financials RPRX
Results | 2019 | Dynamics |